{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:31:00Z","timestamp":1783366260582,"version":"3.54.6"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.phrs.2019.104443","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:59:31Z","timestamp":1567598371000},"page":"104443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Flecainide: Electrophysiological properties, clinical indications, and practical aspects"],"prefix":"10.1016","volume":"148","author":[{"given":"Enrico","family":"Paolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Stronati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Capucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104443_bib0005","series-title":"The ESC Textbook of Cardiovascular Medicine","author":"Camm","year":"2018"},{"key":"10.1016\/j.phrs.2019.104443_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v7.i2.76","article-title":"Flecainide: Current status and perspectives in arrhythmia management","volume":"7","author":"Andrikopoulos","year":"2015","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.65.5.879","article-title":"Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent","volume":"65","author":"Hodges","year":"1982","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104443_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","author":"Aliot","year":"2011","journal-title":"Europace."},{"key":"10.1016\/j.phrs.2019.104443_bib0025","doi-asserted-by":"crossref","DOI":"10.2165\/11599950-000000000-00000","article-title":"Safety of flecainide","author":"Tamargo","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2019.104443_bib0030","first-page":"37","article-title":"State-dependent trapping of flecainide in the cardiac sodium channel","volume":"560","author":"Ramos","year":"2004","journal-title":"J. Physiol. (Paris)"},{"key":"10.1016\/j.phrs.2019.104443_bib0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jacep.2018.03.006","article-title":"Clinical Spectrum of SCN5A mutations","volume":"4","author":"Wilde","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0040","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bph.13807","article-title":"Multiple targets for flecainide action: implications for cardiac arrhythmogenesis","volume":"175","author":"Salvage","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104443_bib0045","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.CIR.97.25.2567","article-title":"Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects","volume":"97","author":"Kirchhof","year":"1998","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104443_bib0050","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.hrthm.2014.07.031","article-title":"Correlation of maternal flecainide concentrations and therapeutic effect in fetal supraventricular tachycardia","volume":"11","author":"Vigneswaran","year":"2014","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131179","article-title":"Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-Propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes","volume":"10","author":"Savio-Galimberti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104443_bib0060","unstructured":"Flecainide - FDA prescribing information, side effects and uses, (n.d.)."},{"key":"10.1016\/j.phrs.2019.104443_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","author":"Tamargo","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104443_bib0070","first-page":"598","volume":"Vol. 8","author":"Furst","year":"2001"},{"key":"10.1016\/j.phrs.2019.104443_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1067\/mcp.2002.125946","article-title":"Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism*","volume":"72","author":"Tennez\u00e9","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2016","key":"10.1016\/j.phrs.2019.104443_bib0080","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)developed with the special contribution of the Europea","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijcard.2014.01.099","article-title":"Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study","volume":"172","author":"Crijns","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/europace\/eut274","article-title":"Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines","volume":"16","author":"Savelieva","year":"2014","journal-title":"Europace."},{"key":"10.1016\/j.phrs.2019.104443_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005049.pub4","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","author":"Lafuente-Lafuente C","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2019.104443_bib0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/hrt.2009.187963","article-title":"Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during \u201cpill-in-the-pocket\u201d treatment","volume":"96","author":"Alboni","year":"2010","journal-title":"Heart."},{"key":"10.1016\/j.phrs.2019.104443_bib0105","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cPill-in-the-Pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104443_bib0110","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(12)60570-4","article-title":"Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial","volume":"380","author":"Kirchhof","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2019.104443_bib0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.hrthm.2004.11.014","article-title":"Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?","volume":"2","author":"Tieleman","year":"2005","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1540-8159.2004.00444.x","article-title":"Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation","volume":"27","author":"Climent","year":"2004","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0130","first-page":"39","article-title":"Silent atrial fibrillation: a critical review","volume":"7","author":"Barbarossa","year":"2014","journal-title":"J. Atr. Fibrillation"},{"key":"10.1016\/j.phrs.2019.104443_bib0135","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(92)91071-B","article-title":"Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias","volume":"70","author":"Hohnloser","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ahj.2007.08.033","article-title":"A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: a Group for Observation and Research on Atrial arrhythmias (PITAGORA","volume":"155","author":"Gulizia","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjcard.2014.11.005","article-title":"Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease","volume":"115","author":"Allen LaPointe","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0150","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0195-668X(03)00311-7","article-title":"VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)","volume":"24","author":"De Simone","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0155","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/europace\/euv462","article-title":"Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation","volume":"18","author":"Capucci","year":"2016","journal-title":"Europace."},{"key":"10.1016\/j.phrs.2019.104443_bib0160","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.ijcard.2013.04.154","article-title":"Amiodarone plus Flecainide combination therapy in patients with Amiodarone refractory paroxysmal atrial fi brillation N\u202f","volume":"168","author":"Kagal","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0165","first-page":"109","article-title":"EPIFLEC, Flecainide controlled-release for prevention of atrial fibrillation relapse","volume":"99","author":"Simon","year":"2006","journal-title":"Arch. Mal. Coeur Vaiss."},{"key":"10.1016\/j.phrs.2019.104443_bib0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0003-3928(02)00183-X","article-title":"Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients","volume":"52","author":"Aliot","year":"2003","journal-title":"Ann. Cardiol. Angeiol. (Paris)."},{"key":"10.1016\/j.phrs.2019.104443_bib0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00005344-200305000-00015","article-title":"Leenhardt, pharmacodynamic equivalence of two flecainide acetate formul","volume":"41","author":"Coumel","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology, J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104443_bib0180","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.ehj.2003.08.002","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with supraventricular arrhythmias\u2014executive summary a report of the american college of Cardiology\/American HeartAssociation task force on practice guidelines and the european society of cardiology com","volume":"24","author":"BlomstromLundqvist","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0185","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/0002-9149(92)91074-E","article-title":"Flecainide in the wolff-parkinson-White syndrome","volume":"70","author":"Crozier","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/clc.4960080603","article-title":"Evaluation of flecainide acetate in rapid atrial fibrillation complicating wolff-parkinson-white syndrome","volume":"8","author":"Kappenberger","year":"1985","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0195","doi-asserted-by":"crossref","first-page":"33A","DOI":"10.1016\/0002-9149(92)91075-F","article-title":"Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome","volume":"70","author":"Camm","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0200","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(01)01773-9","article-title":"Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age","volume":"39","author":"Price","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0205","first-page":"607","article-title":"The use of flecainide in critical neonates and infants with incessant supraventricular tachycardias","volume":"43","author":"Erg\u00fcl","year":"2015","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"10.1016\/j.phrs.2019.104443_bib0210","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"(CAST) investigators, preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"T.C.A.S.T","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"2015","key":"10.1016\/j.phrs.2019.104443_bib0215","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pace.12250","article-title":"Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy, PACE - Pacing Clin","volume":"37","author":"Ermakov","year":"2014","journal-title":"Electrophysiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0225","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104443_bib0235","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"van der Werf","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0240","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0245","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Watanabe","year":"2013","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0250","doi-asserted-by":"crossref","unstructured":"S.M. Al-Khatib, W.G. Stevenson, M.J. Ackerman, W.J. Bryant, D.J. Callans, A.B. Curtis, B.J. Deal, T. Dickfeld, M.E. Field, G.C. Fonarow, A.M. Gillis, M.A. Hlatky, C.B. Granger, S.C. Hammill, J.A. Joglar, G.N. Kay, D.D. Matlock, R.J. Myerburg, R.L. Page, 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Hea, Circulation. (2017) CIR.0000000000000549. doi:10.1161\/CIR.0000000000000549.","DOI":"10.1161\/CIR.0000000000000548"},{"key":"10.1016\/j.phrs.2019.104443_bib0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ipej.2017.10.011","article-title":"The congenital long QT syndrome Type 3: an update","volume":"18","author":"P\u00e9rez-Riera","year":"2018","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"10.1016\/j.phrs.2019.104443_bib0260","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.hrthm.2013.03.001","article-title":"Prevalence, characteristics, and prognosis role of type 1 ST elevation in the peripheral ECG leads in patients with Brugada syndrome","volume":"10","author":"Rollin","year":"2013","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0265","article-title":"Clinical significance of macroscopic T-Wave alternans after sodium channel blocker administration in patients with brugada syndrome","volume":"0","author":"Tada","year":"2007","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0270","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jacc.2016.01.024","article-title":"A new electrocardiographic marker of sudden death in brugada syndrome: the S-Wave in lead i","volume":"67","author":"Cal\u00f2","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.hrthm.2004.11.025","article-title":"Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome","volume":"2","author":"Wolpert","year":"2005","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0280","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht308.P2295","article-title":"Comparison between flecainide and ajmaline challenge in Brugada syndrome patients","volume":"34","author":"Probst","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.104443_bib0285","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1460-9592.2003.00045.x","article-title":"Flecainide test in Brugada syndrome: a reproducible but risky tool","volume":"26","author":"Gasparini","year":"2003","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ipej.2016.06.001","article-title":"Flecainide challenge test: predictors of unmasking of type 1 Brugada ECG pattern among those with non-type 1 Brugada ECG pattern","volume":"16","author":"Prasad","year":"2016","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"10.1016\/j.phrs.2019.104443_bib0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.hrthm.2015.08.038","article-title":"Risk stratification in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing","volume":"13","author":"Adler","year":"2016","journal-title":"Hear. Rhythm."},{"key":"10.1016\/j.phrs.2019.104443_bib0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/hc0102.101354","article-title":"Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-Segment elevation in precordial leads V1 to V3","volume":"105","author":"Brugada","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2019.104443_bib0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2011.08.064","article-title":"Risk Stratification in Brugada Syndrome: Results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) Registry","volume":"59","author":"Priori","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0310","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1055\/s-0031-1299923","article-title":"Meta-analysis of flecainide safety in patients with supraventricular arrhythmias","volume":"52","author":"Wehling","year":"2011","journal-title":"Arzneimittelforschung."},{"key":"10.1016\/j.phrs.2019.104443_bib0315","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2796.2011.02395.x","article-title":"The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events","volume":"270","author":"Almroth","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104443_bib0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.1986.145","article-title":"Pharmacodynamics and side effects of flecainide acetate","volume":"40","author":"Salerno","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104443_bib0325","first-page":"211","article-title":"Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects","volume":"13","author":"Boriani","year":"1993","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104443_bib0330","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00392-010-0129-7","article-title":"Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study","volume":"99","author":"Er","year":"2010","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0335","first-page":"1337","article-title":"European Heart Rhythm Association, Association for European Paediatric and Congenital Cardiology, Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement","volume":"15","author":"Brugada","year":"2013","journal-title":"EP Eur."},{"key":"10.1016\/j.phrs.2019.104443_bib0340","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00246-017-1707-5","article-title":"The safety and effectiveness of flecainide in children in the current era","volume":"38","author":"Cunningham","year":"2017","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.phrs.2019.104443_bib0345","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14767058.2017.1286317","article-title":"Flecainide as first-line treatment for fetal supraventricular tachycardia","volume":"31","author":"Ekiz","year":"2018","journal-title":"J. Matern. Fetal. Neonatal. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819301744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819301744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:03:41Z","timestamp":1760911421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819301744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":69,"alternative-id":["S1043661819301744"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104443","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flecainide: Electrophysiological properties, clinical indications, and practical aspects","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104443"}}